Healthcare perspectives from The Economist Intelligence Unit

Color

#DB444B

Hero Carousel

Spotlight

Bringing healthcare to hard-hit areas in Bangladesh

YouTube

https://www.youtube.com/channel/UCQDMOSbJtqrtNzif5rS22OQ

Slideshare

http://www.slideshare.net/economistintelligenceunit

Pinterest

https://www.pinterest.com/theeiu/

Podcast | Healthcare sustainability

Healthcare sustainability

Into the New World: The Covid-19 Pandemic’s Impact on Innovation

The Covid-19 pandemic is the most significant global disruption since World War II and the first truly global public health crisis in the modern era. Entire industries have ground to a halt; international travel has receded to its lowest level in 75 years; nearly all of the world’s leading economies are in recession; and at the time of publication, more than one million people have died from the virus and its complications. As the pandemic forces profound change in all aspects of society, technology is playing a starring role in enabling organisations to respond to disruption.

Podcast | Vaccine development: A race to the finish line

Vaccine development: A race to the finish line

Racism is a public health issue

Racism is still pernicious, pervasive and cutting short the lives of black Americans to this day.

State of patient centricity 2020: Advancing from patient-first intentions to true co-creation

Patient centricity is a near-universal goal in pharmaceutical research and development, but one without a commonly accepted definition. The challenge now is putting it into practice and understanding its impact on clinical trials. This Economist Intelligence Unit study, sponsored by Medidata, draws on insights from patient advocates, leading pharmaceutical and clinical research industry executives and extensive desk research.

The workplace response to neurological conditions: A focus on migraine, multiple sclerosis and Alzheimer’s disease

Migraine, multiple sclerosis (MS) and Alzheimer’s disease (AD) affect over 1.3bn people globally. The report  looks at the impact of these three neurological conditions on both patients and carers in the workplace.

Value-based healthcare in Sweden: Reaching the next level

The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.

Women’s health and well-being


How do definitions of women’s well-being vary by region, age and income? Our new infographic, sponsored by Merck Consumer Health explores.

The United States Out of the Shadows Index: shining a light on the prevention of and response to child sexual exploitation and abuse in the US

Estimations of the scale, scope and cost of child sexual exploitation and abuse (CSEA) in the United States are startling. The Centers for Disease Control and Prevention reports that approximately one in four girls and one in 20 boys in the US will experience sexual abuse during childhood,1 while child protective services agencies reported 59,000 cases—or a new case every nine minutes—of child sexual abuse in 2021 alone.2

Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape

By December 2020, several potential covid-19 vaccines were showing promise in clinical trials. And by the middle of 2021, a vaccine was available to the public. Very few people had been optimistic that such a feat could be achieved. In many ways, it was a perfect storm. The fast development of covid-19 vaccines benefited from years of previous research on related viruses and vaccine trials that used mRNA. It’s said the research matured at just the right time, and that mRNA technology would not have been ready even five years ago.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week